Somaxon Pharmaceuticals (SOMX) Posts Q4 Loss of 21c/Share, Inline with the Street
Tweet
Share
E-mailGet Alerts SOMX Hot Sheet
Price: $3.00 --0%
Financial Fact:
Total operating costs and expenses: 6.62M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Total operating costs and expenses: 6.62M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) reported Q4 EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $4.42 million.
Lowered its FY12 total non-GAAP operating expenses to $15-$16 million.
For earnings history and earnings-related data on Somaxon Pharmaceuticals, Inc. (SOMX) click here.
Lowered its FY12 total non-GAAP operating expenses to $15-$16 million.
For earnings history and earnings-related data on Somaxon Pharmaceuticals, Inc. (SOMX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'
- Investing.com’s stocks of the week
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
